scholarly journals Menopausal hormone therapy, blood thrombogenicity, and development of white matter hyperintensities in women of the Kronos Early Estrogen Prevention Study

Menopause ◽  
2020 ◽  
Vol 27 (3) ◽  
pp. 305-310 ◽  
Author(s):  
Muthuvel Jayachandran ◽  
Brian D. Lahr ◽  
Kent R. Bailey ◽  
Virginia M. Miller ◽  
Kejal Kantarci
Keyword(s):  
White Matter ◽  
Hormone Therapy ◽  
White Matter Hyperintensities ◽  
Menopausal Hormone Therapy ◽  
Prevention Study

MRI white matter hyperintensities: Three-year follow-up of the Austrian Stroke Prevention Study

Neurology ◽  
1999 ◽  
Vol 53 (1) ◽  
pp. 132-132 ◽  
Author(s):  
R. Schmidt ◽  
F. Fazekas ◽  
P. Kapeller ◽  
H. Schmidt ◽  
H.-P. Hartung
Keyword(s):  
White Matter ◽  
Stroke Prevention ◽  
White Matter Hyperintensities ◽  
Prevention Study

scholarly journals Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial

Neurology ◽  
2018 ◽  
Vol 90 (16) ◽  
pp. e1404-e1412 ◽  
Author(s):  
Kejal Kantarci ◽  
Nirubol Tosakulwong ◽  
Timothy G. Lesnick ◽  
Samantha M. Zuk ◽  
Val J. Lowe ◽  
...  
Keyword(s):  
White Matter ◽  
Hormone Therapy ◽  
Brain Structure ◽  
Cognitive Change ◽  
Menopausal Hormone Therapy ◽  
Pittsburgh Compound B ◽  
Ventricular Volumes ◽  
Menopausal Women ◽  
Dorsolateral Prefrontal ◽  
Global Brain

ObjectiveThe effects of 2 frequently used formulations of menopausal hormone therapy (mHT) on brain structure and cognition were investigated 3 years after the end of a randomized, placebo-controlled trial in recently menopausal women with good cardiovascular health.MethodsParticipants (aged 42–56 years; 5–36 months past menopause) were randomized to one of the following: 0.45 mg/d oral conjugated equine estrogen (oCEE); 50 μg/d transdermal 17β-estradiol (tE2); or placebo pills and patch for 4 years. Oral progesterone (200 mg/d) was given to mHT groups for 12 days each month. MRIs were performed at baseline, at the end of 4 years of mHT, and 3 years after the end of mHT (n = 75). A subset of participants also underwent Pittsburgh compound B–PET (n = 68).ResultsVentricular volumes increased more in the oCEE group compared to placebo during the 4 years of mHT, but the increase in ventricular volumes was not different from placebo 3 years after the discontinuation of mHT. Increase in white matter hyperintensity volume was similar in the oCEE and tE2 groups, but it was statistically significantly greater than placebo only in the oCEE group. The longitudinal decline in dorsolateral prefrontal cortex volumes was less in the tE2 group compared to placebo, which correlated with lower cortical Pittsburgh compound B uptake. Rates of global cognitive change in mHT groups were not different from placebo.ConclusionsThe effects of oCEE on global brain structure during mHT subside after oCEE discontinuation but white matter hyperintensities continue to increase. The relative preservation of dorsolateral prefrontal cortical volume in the tE2 group over 7 years indicates that mHT may have long-term effects on the brain.Classification of evidenceThis study provides Class III evidence that the rates of change in global brain volumes and cognitive function in recently menopausal women receiving mHT (tE2 or oCEE) were not significantly different from women receiving placebo, as measured 3 years after exposure to mHT.

scholarly journals Associations of pituitary-ovarian hormones and white matter hyperintensities in recently menopausal women using hormone therapy

Menopause ◽  
2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Juliana M. Kling ◽  
Virginia M. Miller ◽  
Nirubol Tosakulwong ◽  
Timothy Lesnick ◽  
Kejal Kantarci
Keyword(s):  
White Matter ◽  
Hormone Therapy ◽  
White Matter Hyperintensities ◽  
Ovarian Hormones ◽  
Menopausal Women

Menopausal hormone therapy and uterine cancer: the acceptability of the tandem

GYNECOLOGY ◽  
2018 ◽  
Vol 20 (6) ◽  
pp. 42-47
Author(s):  
O V Yakushevskaya ◽  
S V Yureneva ◽  
A E Protasova ◽  
G N Khabas ◽  
M R Dumanovskaya
Keyword(s):  
Hormone Therapy ◽  
Uterine Cancer ◽  
Menopausal Hormone Therapy ◽  
Medical Rehabilitation ◽  
Cytostatic Treatment ◽  
Systematic Analysis ◽  
Strict Adherence ◽  
Patient Profile ◽  
The Past

The aim of the work is to conduct a systematic analysis of the available research results on the possibility of using menopausal hormone therapy (MHT) in patients who successfully completed the treatment of endometrial cancer (EC). Materials and methods. The review includes data from foreign articles published in PubMed and Medline, and domestic works published on elibrary.ru over the past 40 years. Results. The results obtained allow us to consider MHT as an independent method of medical rehabilitation for women who have undergone EC. A clear patient profile should be established, allowing the use of this method, with strict adherence to health monitoring. Conclusion Patients who have successfully completed the treatment of EC require the creation of special rehabilitation conditions in the interests of maintaining health and quality of life and should be under the close attention of the doctor. Argumented approaches to the appointment of MHT in such patients will avoid complications associated with estrogen deficiency after surgery, radiation with or without systemic (cytostatic) treatment methods.

The role of orexin A in pathophysiological mechanisms of sleep disorder in postmenopausal women

GYNECOLOGY ◽  
2020 ◽  
Vol 22 (1) ◽  
pp. 50-54
Author(s):  
Zukhra Kh. Ebzieva ◽  
Svetlana V. Yureneva ◽  
Tatiana Yu. Ivanets
Keyword(s):  
Hormone Therapy ◽  
Sleep Disorder ◽  
Postmenopausal Women ◽  
Menopausal Hormone Therapy ◽  
Reproductive Age ◽  
Vasomotor Symptoms ◽  
Women Of Reproductive Age ◽  
Orexin A ◽  
Group 1

Aim. To conduct a comparative analysis of serum orexin A levels in women of different age periods with and without sleep disorder and vasomotor symptoms. To evaluate the dynamics of orexin A levels under menopausal hormone therapy. Materials and methods. The study included 50 postmenopausal women and 30 women of reproductive age with a regular menstrual cycle. Using block randomization, patients are divided into 3 groups: group 1 (main group), n=25, -STRAW+ 10 (+1b and +1c), patients with sleep disorder and vasomotor symptoms; group 2 (comparison group), n=25, STRAW+ 10 (+1b and +1c), patients with vasomotor symptoms without sleep disorder; group 3 (control group), n=30, STRAW+ 10 (-4), women of reproductive age without sleep disorder. Group 1 patients were given menopausal hormone therapy. A comparative analysis was carried out using the questionnaire for assessing menopausal symptoms severity by the Greene Scale (the Greene Climacteric Scale) and Rating Scale for subjective sleep characteristics. After 12 weeks of treatment, a control examination was performed. Results. In group 1 women, the serum orexin A levels were significantly higher compared to the women without the symptoms. The link between the orexin A levels and menopause syndrome severity was established. A significant decrease in the menopausal symptoms severity after 12 weeks of menopausal hormone therapy was shown. It was accompanied by a 1,3-fold decrease in orexin A levels. Conclusions. The obtained data indicate the possible role of orexin A and the orexin neuropeptide system in the pathogenesis of sleep disorder and vasomotor symptoms in postmenopausal women.

Sign in / Sign up

Export Citation Format

Share Document